Ideally, action to prevent communicable diseases concentrates on safeguarding people from exposure to infection by environmental measures that will eliminate natural reservoirs or interrupt paths of transmission. The main advantage of this approach is that it does not depend on the cooperation of individuals. Where such measures are impractical, it may be possible to persuade people to change their behaviour in ways that avoid unnecessarily exposing themselves to harmful agents, which can be equally effective. The use of vaccines to stimulate or enhance specific host immunity is in many ways the least satisfactory preventive option. This is partly because vaccination affords no guarantee of protection to the individual and, more seriously, because it involves the parenteral injection of foreign proteins in the form of whole (or components of) killed microbes or the administration of living (attenuated) organisms, which inevitably carries risks of evoking adverse reactions in a proportion of vaccinees. Nonetheless, active immunisation is the only practical strategy for the prevention of many infections. It has proved highly successful in disease control, and serious reactions are comparatively rare. Therefore vaccines are likely to remain an essential weapon in the public health armamentarium, and research to improve the efficacy, to reduce their toxicity and to develop policies for their optimum deployment must continue to occupy a high priority.
In this paper my aim is to identify and discuss some topical issues related to the development of vaccines and policies for their use, particularly those currently in routine use for childhood immunisation in the UK. Vaccines also have a role in the management of outbreaks of some infections in which they can be used to interrupt spread. When live attenuated poliovirus vaccine was first introduced, monovalent vaccines were used to interrupt epidemics due to a different poliovirus type, on the principle of competitive colonisation of the bowel.13 This use of live vaccine remains recommended practice, although now trivalent vaccine would be used. In some other infections vaccines are used in the face of an outbreak, but in these circumstances the main purpose is to offer individual protection, and the population benefit is seen as a useful bonus rather than as the prime strategy.
TRIALS OF THE EFFICACY AND SAFETY OF NEW VACCINES
The production of new or improved vaccines will require the conduct of large field trials designed to measure not only efficacy but also safety to ever more stringent standards. The design of appropriate trials, never an easy proposition, under modern conditions will be even more difficult for a number of reasons.
First, the evaluation of marginal improvements in the immunogenicity and protective efficacy of vaccines will require very large numbers of participants which creates problems of logistics and cost. The second difficulty arises from the increasing public concern about adverse reactions and the effect this is likely to have on the availability of volunteers and ethical acceptability of trials, particularly where infants and children are involved, as they must be since they are the prime target group for many vaccines. Thirdly, trials are likely to be critically concerned with measuring reductions in the frequency of rare but serious reactions, compared with current vaccines. A particular example is the new component pertussis vaccine. The incidence of encephalopathy after current pertussis vaccines is so rare that no ordinary field trial could measure a significant change in the risk.14 In such cases we shall probably have to depend on indirect indices of toxicity derived from animal experiments and extrapolation from the incidence of less severe reactions, coupled with prolonged and careful monitoring of reactions to vaccines once they have been accepted into routine use. Finally, careful and sustained surveillance will also be required to monitor the implementation of vaccine policy, the incidence of disease and the duration of immunity.
The public and the profession need to accept and debate the dilemmas presented by carrying out adequate trials of new or improved vaccines in present circumstances, and also to decide what risks, if any, can be accepted in any recommendations for their routine use after initial trials.
Current immunisation policies
Health authorities and paediatricians are sometimes criticised for lack of consistency in their recommendations on vaccine schedules. In view of the many variables that enter the equation of risks and benefits, some of which are hard to quantify, as well as the logistic problems and economic factors that effect the design of schedules, it is not surprising that they feel compelled to modify their advice from time to time nor that they do not always agree. However, too frequent changes should be avoided since they tend to undermine the credibility of the advice and cause confusion among parents and those responsible for administering the vaccines, which may result in low vaccine acceptance rates.
A Acceptance rates, at around 80% on average, are high enough to have eliminated these diseases as important public health problems. Rates for pertussis vaccine, once equally high, have plummeted in the wake of publicity given to cases of alleged brain damage due to the vaccine but are slowly recovering. The effectiveness of the vaccine has been challenged, but the return of epidemics that followed the fall in immunisation rates leaves little doubt that it did control the disease. It is also clear now that the dangers of the vaccine have been grossly exaggerated.5 On the balance of risks and benefits, therefore, its use has been consistently recommended in the UK. It is to be hoped that confidence in the vaccine will soon be restored and that the disease will once more be brought under control.
Measles vaccine is highly effective and generally safe, and the eradication of the disease is regarded as a feasible target nationally"7 and even globally."8 Yet acceptance rates remain very low in many countries, 
